留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
中华医学会罕见病分会, 中国研究型医院学会罕见病分会, 中国罕见病联盟, 北京罕见病诊疗与保障学会, Bartter综合征中国专家组. Bartter综合征诊疗中国专家共识(2023)[J]. 协和医学杂志, 2023, 14(4): 744-757. doi: 10.12290/xhyxzz.2023-0207
引用本文: 中华医学会罕见病分会, 中国研究型医院学会罕见病分会, 中国罕见病联盟, 北京罕见病诊疗与保障学会, Bartter综合征中国专家组. Bartter综合征诊疗中国专家共识(2023)[J]. 协和医学杂志, 2023, 14(4): 744-757. doi: 10.12290/xhyxzz.2023-0207
Chinese Society of Rare Diseases, Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society. Expert Consensus for the Diagnosis and Treatment of Bartter Syndrome in China(2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 744-757. doi: 10.12290/xhyxzz.2023-0207
Citation: Chinese Society of Rare Diseases, Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society. Expert Consensus for the Diagnosis and Treatment of Bartter Syndrome in China(2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 744-757. doi: 10.12290/xhyxzz.2023-0207

Bartter综合征诊疗中国专家共识(2023)

doi: 10.12290/xhyxzz.2023-0207
基金项目: 

国家重点研发计划 2022ZD0116003

中央高水平医院临床科研业务费 2022-PUMCH-B-019

中央高水平医院临床科研业务费 2022-PUMCH-D-002

首都卫生发展科研专项 CFH 2020-2-4018

中国医学科学院医学与健康科技创新工程 2021-I2M-1-003

详细信息
  • 中图分类号: R596; R692; R692.5

Expert Consensus for the Diagnosis and Treatment of Bartter Syndrome in China(2023)

Funds: 

National Key R & D Program of China 2022ZD0116003

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-019

National High Level Hospital Clinical Research Funding 2022-PUMCH-D-002

Capital's Funds for Health Improvement and Research CFH 2020-2-4018

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-003

  • 摘要: Bartter综合征是一种罕见的遗传性失盐性肾病,以继发性醛固酮增多症伴低血钾、低氯性代谢性碱中毒、血压正常或偏低为主要临床特点。可出现早产、低血容量、室性心律失常、横纹肌溶解、肾功能衰竭、生长发育迟缓、感音神经性耳聋等临床情况,疾病危害大。近年来,Bartter综合征相关研究取得了长足进步。中华医学会罕见病分会、中国研究型医院学会罕见病分会、中国罕见病联盟、北京罕见病诊疗与保障学会联合相关领域专家全面复习了Bartter综合征相关文献,基于最新循证医学证据,在Bartter综合征的临床表现与分型、诊断、治疗、并发症管理方面达成共识,为临床规范化诊疗提供了依据。
    作者贡献:本专家共识由中华医学会罕见病分会、中国研究型医院学会罕见病分会、中国罕见病联盟、北京罕见病诊疗与保障学会发起,陈丽萌、陈朝英、张抒扬牵头成立共识制订工作组,编写组成员共同起草了共识初稿,专家组成员共同进行讨论和投票。
    利益冲突:所有参与本共识制订的人员均声明不存在利益冲突
    专家组成员 (按姓氏首字母排序):
    陈朝英(首都儿科研究所附属儿童医院肾脏内科),陈丽萌(北京协和医院肾内科),陈崴(中山大学附属第一医院肾内科),陈晓巍(北京协和医院耳鼻喉科),程虹(首都医科大学附属北京安贞医院肾内科),程庆砾(中国人民解放军总医院肾脏病科),高劲松(北京协和医院妇产科),韩飞(浙江大学医学院附属第一医院肾脏病中心),李月红(北京清华长庚医院肾内科),刘晓清(北京协和医院感染内科临床流行病学教研室),刘小荣(首都医科大学附属北京儿童医院肾病科),刘雅萍(中国医学科学院基础医学研究所医学遗传学系),马坤岭(浙江大学医学院附属第二医院肾脏内科),毛建华(浙江大学医学院附属儿童医院肾脏内科), 毛永辉(北京医院肾脏内科),梅长林(上海长征医院肾脏病科),聂敏(北京协和医院内分泌科),童安莉(北京协和医院内分泌科),王墨(重庆医科大学附属儿童医院肾脏内科),王悦(北京大学第三医院肾内科),魏珉(北京协和医院儿科),许辉(中南大学湘雅医院肾脏内科),杨琼琼(中山大学孙逸仙纪念医院肾内科),姚丽(中国医科大学附属第一医院肾脏内科),易杰(北京协和医院麻醉科),张爱华(南京医科大学附属儿童医院肾脏科),张抒扬(北京协和医院心内科,疑难重症及罕见病国家重点实验室),郑亚莉(宁夏回族自治区人民医院肾脏内科),郑智华(中山大学附属第七医院肾脏病中心)
    执笔者:张磊(北京协和医院肾内科),彭晓艳(首都儿科研究所附属儿童医院肾脏内科),杨宏仙(首都儿科研究所附属儿童医院肾脏内科),简珊(北京协和医院儿科),樊晓红(北京协和医院肾内科),蒋兰萍(中山大学附属第一医院肾内科),董源(北京协和医院肾内科),赵若环(北京协和医院肾内科),吕宁(北京协和医院肾内科),乐偲(北京协和医院肾内科),涂娟(首都儿科研究所附属儿童医院肾脏内科),陈朝英(首都儿科研究所附属儿童医院肾脏内科),陈丽萌(北京协和医院肾内科)
  • 图  1  BS鉴别诊断流程图

    TTKG:跨小管钾梯度;RAS:肾素-血管紧张素系统;GS:Gitelman综合征;BS:同表 3

    图  2  BS相关基因在肾小管各段的分布及对应的BS亚型

    BS、NKCC2、ROMK、ClC-Kb、Barttin、ClC-Ka+b、MAGE-D2:同表 3

    表  1  本共识证据等级的定义

    证据等级 定义
    1a 总结多项随机对照研究的荟萃分析
    1b 至少有1项随机对照研究
    2a 至少有1项设计良好的对照研究,但未随机分组
    2b 至少有1项设计良好的其他类型准实验研究
    3 设计良好的非实验性描述性研究,如比较研究、相关性研究、病例研究等
    4 专家委员会的报告或观点,以及权威专家的临床经验
    下载: 导出CSV

    表  2  本共识推荐强度的定义

    推荐强度 定义 证据等级
    A(强) 有1项或多项高质量随机对照研究回答该临床问题 1a、1b
    B(中) 针对该问题,有设计良好的临床研究但未随机分组 2a、2b、3
    C(弱) 专家委员会的报告或观点,以及权威专家的临床经验,提示本领域需进行高质量的临床研究 4
    下载: 导出CSV

    表  3  BS分型及临床特点[5]

    指标 分型
    BS 1型 BS 2型 BS 3型 BS 4a型 BS 4b型 BS 5型
    OMIM 601678 241200 607364 602522 613090 300971
    致病基因 SLC12A1 KCNJ1 CLCNKB BSND CLCNKA+B MAGED2
    遗传方式 AR AR AR AR DR XLR
    基因产物 NKCC2 ROMK ClC-Kb Barttin ClC-Ka+b MAGE-D2
    发病年龄 产前/新生儿 产前/新生儿 婴幼儿 产前/新生儿 产前/新生儿 产前/新生儿
    羊水过多 ++ ++ ± ++ / ++~+++
    分娩孕周(周) 32(29~34) 33(31~35) 37(36~41) 31(28~35) / 29(21~37)
    多尿 ++ ++ ± ++ ++ ++
    生长发育障碍 ++ ++ ± ++ ++ -
    感音神经性耳聋 - - - + + -
    高尿钙/肾钙质沉着 ++/++ ++/++ ± ± ± ±
    低钾血症 + + ++ ++ ++ +
    低氯血症 ± ± + + + ±
    低镁血症 - - ± ± ± ±
    BS:Bartter综合征;OMIM:人类基因和遗传疾病数据库;AR:常染色体隐性遗传;DR:双基因隐性遗传;XLR:X连锁隐性遗传;NKCC2:钠钾氯协同转运蛋白;ROMK:肾外髓钾通道;ClC-Kb:氯离子电压门控通道Kb;Barttin:氯离子通道β亚单位;ClC-Ka+b:氯离子电压门控通道Ka和Kb;MAGE-D2:黑色素瘤相关抗原D2;++,+++:症状突出;+:存在该症状;±:轻度或存在变异;-:无该症状;/:缺乏相应资料
    下载: 导出CSV

    表  4  BS低钾血症严重程度分级

    指标 分级
    1级 2级 3级 4级
    血钾(mmol/L) 3.0~3.4 2.5~2.9 2.0~2.4,或强效替代治疗,或住院治疗 <2.0,或低钾伴轻瘫、肠梗阻,或危及生命的心律失常
    BS:同表 3
    下载: 导出CSV

    表  5  BS各亚型相关基因、蛋白的例数及占比(n=766)

    BS分型 基因 染色体位点 蛋白 蛋白功能 n(%)
    1型 SLC12A1 15q21.1 NKCC2 重吸收钠离子、钾离子和氯离子 124(16.2)
    2型 KCNJ1 11q24.3 ROMK 小管上皮细胞内的钾离子回流至小管腔内 106(13.8)
    3型 CLCNKB 1p36.13 ClC-Kb 负责基底膜侧氯离子的重吸收 454(59.3)
    4a型 BSND 1p32.3 Barttin 是ClC-Ka和ClC-Kb氯离子通道的β亚单位 46(6.0)
    4b型 CLCNKA+B 1p36.13 ClC-Ka+b 负责基底膜侧氯离子的重吸收 6(0.8)
    5型 MAGED2 Xp11.21 MAGE-D2 辅助NKCC2和NCC表达于细胞膜上 30(3.9)
    NCC:钠氯协同转运蛋白; BS、NKCC2、ROMK、ClC-Kb、Barttin、ClC-Ka+b、MAGE-D2:同表 3
    下载: 导出CSV

    表  6  不同类型BS对利尿剂的反应

    相关研究 BS分型 呋塞米试验 氢氯噻嗪试验
    Nozu等[48](n=13) 1型 无反应 有反应
    2型 有反应 有反应
    3型 有反应 无反应
    Colussi等[49](n=7) 1型 - 有反应
    3型 - 反应较弱
    BS:同表 3;-:缺乏相关数据
    下载: 导出CSV
  • [1] Konrad M, Nijenhuis T, Ariceta G, et al. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders[J]. Kidney Int, 2021, 99: 324-335. doi:  10.1016/j.kint.2020.10.035
    [2] Graham AJ, Gelfand G, McFadden SD, et al. Levels of evidence and grades of recommendations in general thoracic surgery[J]. Can J Surg, 2004, 47: 461-465.
    [3] 王建祥, 张奉春, 刘晓清, 等. 中国成人血小板减少症诊疗专家共识[J]. 中华内科杂志, 2020, 59: 498-510. doi:  10.3760/cma.j.cn112138-20200424-00419
    [4] Jones J, Hunter D. Consensus methods for medical and health services research[J]. BMJ, 1995, 311: 376-380. doi:  10.1136/bmj.311.7001.376
    [5] Bamgbola OF, Ahmed Y. Differential diagnosis of perinatal Bartter, Bartter and Gitelman syndromes[J]. Clin Kidney J, 2021, 14: 36-48. doi:  10.1093/ckj/sfaa172
    [6] Seys E, Andrini O, Keck M, et al. Clinical and genetic spectrum of Bartter syndrome type 3[J]. J Am Soc Nephrol, 2017, 28: 2540-2552. doi:  10.1681/ASN.2016101057
    [7] Legrand A, Treard C, Roncelin I, et al. Prevalence of novel MAGED2 mutations in antenatal Bartter syndrome[J]. Clin J Am Soc Nephrol, 2018, 13: 242-250. doi:  10.2215/CJN.05670517
    [8] Lee HS, Cheong HI, Ki CS. A case of antenatal Bartter syndrome with sensorineural deafness[J]. J Pediatr Endocrinol Metab, 2010, 23: 1077-1081.
    [9] Finer G, Shalev H, Birk OS, et al. Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome[J]. J Pediatr, 2003, 142: 318-323. doi:  10.1067/mpd.2003.100
    [10] Birkenhager R, Otto E, Schurmann MJ, et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure[J]. Nat Genet, 2001, 29: 310-314. doi:  10.1038/ng752
    [11] Shalev H, Ohali M, Kachko L, et al. The neonatal variant of Bartter syndrome and deafness: preservation of renal function[J]. Pediatrics, 2003, 112: 628-633. doi:  10.1542/peds.112.3.628
    [12] Takemori S, Tanigaki S, Nozu K, et al. Prenatal diagnosis of MAGED2 gene mutation causing transient antenatal Bartter syndrome[J]. Eur J Med Genet, 2021, 64: 104308. doi:  10.1016/j.ejmg.2021.104308
    [13] Laghmani K, Beck BB, Yang SS, et al. Polyhydramnios, transient antenatal Bartter's syndrome, and MAGED2 mutations[J]. N Engl J Med, 2016, 374: 1853-1863. doi:  10.1056/NEJMoa1507629
    [14] 韩玥, 郎艳华, 林毅, 等. 42例3型巴特综合征CLCNKB基因变异分析和基因型/表型研究[J]. 中华肾脏病杂志, 2019, 35: 499-506. doi:  10.3760/cma.j.issn.1001-7097.2019.07.004
    [15] London S, Levine MA, Li D, et al. Hypocalcemia as the initial presentation of type 2 Bartter syndrome: a family report[J]. J Clin Endocrinol Metab, 2022, 107: 1679-1688. doi:  10.1210/clinem/dgac130
    [16] Brum S, Rueff J, Santos JR, et al. Unusual adult-onset manifestation of an attenuated Bartter's syndrome type Ⅳ renal phenotype caused by a mutation in BSND[J]. Nephrol Dial Transplant, 2007, 22: 288-289.
    [17] García Castaño A, Pérez de Nanclares G, Madariaga L, et al. Poor phenotype-genotype association in a large series of patients with Type Ⅲ Bartter syndrome[J]. PloS One, 2017, 12: e0173581. doi:  10.1371/journal.pone.0173581
    [18] Palazzo V, Raglianti V, Landini S, et al. Clinical and genetic characterization of patients with Bartter and Gitelman syndrome[J]. Int J Mol Sci, 2022, 23: 5641. doi:  10.3390/ijms23105641
    [19] 韩玥, 林毅, 孙清, 等. 中国16例巴特综合征基因变异分析和治疗随访研究[J]. 中华肾脏病杂志, 2017, 33: 573-581. doi:  10.3760/cma.j.issn.1001-7097.2017.08.003
    [20] Khandelwal P, Sabanadesan J, Sinha A, et al. Isolated nephrocalcinosis due to compound heterozygous mutations in renal outer medullary potassium channel[J]. CEN Case Rep, 2020, 9: 232-236. doi:  10.1007/s13730-020-00464-y
    [21] 王小娟, 陈琛, 杜婷婷, 等. 成年Ⅲ型Bartter综合征1例并文献复习[J]. 内科急危重症杂志, 2016, 22: 62-63. https://www.cnki.com.cn/Article/CJFDTOTAL-NKJW201601026.htm
    [22] 于迎, 潘晓霞, 任红, 等. 成人经典型Bartter综合征家系CLCNKB基因变异的研究[J]. 中华肾脏病杂志, 2010, 26: 598-602. doi:  10.3760/cma.j.issn.1001-7097.2010.08.007
    [23] 韩玥, 王芳, 王彦刚, 等. 成年发病的2型巴特综合征1例[J]. 中华内科杂志, 2017, 56: 679-680. doi:  10.3760/cma.j.issn.0578-1426.2017.09.012
    [24] Huang L, Luiken GP, van Riemsdijk IC, et al. Nephrocalcinosis as adult presentation of Bartter syndrome type Ⅱ[J]. Neth J Med, 2014, 72: 91-93.
    [25] Kleta R, Bockenhauer D. Salt-losing tubulopathies in children: what's new, what's controversial?[J]. J Am Soc Nephrol, 2018, 29: 727-739. doi:  10.1681/ASN.2017060600
    [26] Malafronte C, Borsa N, Tedeschi S, et al. Cardiac arrhythmias due to severe hypokalemia in a patient with classic Bartter disease[J]. Pediatr Nephrol, 2004, 19: 1413-1415. doi:  10.1007/s00467-004-1611-0
    [27] Cortesi C, Bettinelli A, Emma F, et al. Severe syncope and sudden death in children with inborn salt-losing hypokalaemic tubulopathies[J]. Nephrol Dial Transplant, 2005, 20: 1981-1983. doi:  10.1093/ndt/gfh893
    [28] Zanolari Calderari M, Vigier RO, Bettinelli A, et al. Electrocardiographic QT prolongation and sudden death in renal hypokalemic alkalosis[J]. Nephron, 2002, 91: 762-763. doi:  10.1159/000065045
    [29] Cortesi C, Lava SA, Bettinelli A, et al. Cardiac arrhythmias and rhabdomyolysis in Bartter-Gitelman patients[J]. Pediatr Nephrol, 2010, 25: 2005-2008. doi:  10.1007/s00467-010-1580-4
    [30] Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2017, 91: 24-33. doi:  10.1016/j.kint.2016.09.046
    [31] 刘帆, 孙妍, 徐潮, 等. 低钾血症中遗传性肾小管疾病的临床特点分析[J]. 临床荟萃, 2021, 36: 436-441. doi:  10.3969/j.issn.1004-583X.2021.05.010
    [32] Walsh PR, Tse Y, Ashton E, et al. Clinical and diagnostic features of Bartter and Gitelman syndromes[J]. Clin Kidney J, 2018, 11: 302-309. doi:  10.1093/ckj/sfx118
    [33] 韩玥, 郎艳华, 肖淑佼, 等. 中国5例2型巴特综合征KCNJ1基因变异分析和临床表型研究[J]. 中华肾脏病杂志, 2020, 36: 115-122. doi:  10.3760/cma.j.issn.1001-7097.2020.02.008
    [34] Bettinelli A, Borsa N, Bellantuono R, et al. Patients with biallelic mutations in the chloride channel gene CLCNKB: long-term management and outcome[J]. Am J Kidney Dis, 2007, 49: 91-98. doi:  10.1053/j.ajkd.2006.10.001
    [35] Scognamiglio R, Negut C, Calò LA. Aborted sudden cardiac death in two patients with Bartter's/Gitelman's syndromes[J]. Clin Nephrol, 2007, 67: 193-197. doi:  10.5414/CNP67193
    [36] Maruyama H, Shinno Y, Fujiwara K, et al. Nephrocal-cinosis and placental findings in neonatal bartter syndrome[J]. AJP Rep, 2013, 3: 21-24.
    [37] Brochard K, Boyer O, Blanchard A, et al. Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome[J]. Nephrol Dial Transplant, 2009, 24: 1455-1464. doi:  10.1093/ndt/gfn689
    [38] 李新岩, 姜艳, 许莉军, 等. KCNJ1新的复合杂合变异致Bartter综合征Ⅱ型临床和遗传分析[J]. 中华内科杂志, 2017, 56: 760-762. doi:  10.3760/cma.j.issn.0578-1426.2017.10.010
    [39] Yamazaki H, Nozu K, Narita I, et al. Atypical phenotype of type Ⅰ Bartter syndrome accompanied by focal segmental glomerulosclerosis[J]. Pediatr Nephrol, 2009, 24: 415-418. doi:  10.1007/s00467-008-0999-3
    [40] Adachi M, Tajima T, Muroya K, et al. Classic Bartter syndrome complicated with profound growth hormone deficiency: a case report[J]. J Med Case Rep, 2013, 7: 283. doi:  10.1186/1752-1947-7-283
    [41] Garnier ADS, Vargas-Poussou R, Oury JF, et al. Bartter syndrome prenatal diagnosis based on amniotic fluid biochemical analysis[J]. Pediatr Res, 2010, 67: 300-303. doi:  10.1203/PDR.0b013e3181ca038d
    [42] Allaf B, Dreux S, Schmitz T, et al. Amniotic fluid biochemistry in isolated polyhydramnios: a series of 464 cases[J]. Prenat Diagn, 2015, 35: 1331-1335. doi:  10.1002/pd.4700
    [43] 中国研究型医院学会罕见病分会, 中国罕见病联盟, 北京罕见病诊疗与保障学会, 等. Gitelman综合征诊疗中国专家共识(2021版)[J]. 协和医学杂志, 2021, 12: 902-912. doi:  10.12290/xhyxzz.2021-0555
    [44] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17: 405-424. doi:  10.1038/gim.2015.30
    [45] Marcoux AA, Slimani S, Tremblay LE, et al. Endocytic recycling of Na(+) -K(+) -Cl(-) cotransporter type 2: importance of exon 4[J]. J Physiol, 2019, 597: 4263-4276. doi:  10.1113/JP278024
    [46] Marcoux AA, Slimani S, Tremblay LE, et al. Regulation of Na(+)-K(+)-Cl(-) cotransporter type 2 by the with no lysine kinase-dependent signaling pathway[J]. Am J Physiol Cell Physiol, 2019, 317: 20-30. doi:  10.1152/ajpcell.00041.2019
    [47] 彭晓艳, 蒋兰萍, 袁涛, 等. 氯离子清除试验在Gitelman综合征鉴别诊断中的应用[J]. 中国医学科学院学报, 2016, 38: 275-282. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYKX201603006.htm
    [48] Nozu K, Iijima K, Kanda K, et al. The pharmacological characteristics of molecular-based inherited salt-losing tubulopathies[J]. J Clin Endocrinol Metab, 2010, 95: 511-518. doi:  10.1210/jc.2010-0392
    [49] Colussi G, Bettinelli A, Tedeschi S, et al. A thiazide test for the diagnosis of renal tubular hypokalemic disorders[J]. Clin J Am Soc Nephrol, 2007, 2: 454-460. doi:  10.2215/CJN.02950906
    [50] Nam G, Cho A, Park MH. A rare cause of refractory severe polyhydramnios: antenatal Bartter syndrome[J]. Medicina, 2021, 57: 272. doi:  10.3390/medicina57030272
    [51] Dane B, Dane C, Aksoy F, et al. Antenatal Bartter syndrome: analysis of two cases with placental findings[J]. Fetal Pediatr Pathol, 2010, 29: 121-126. doi:  10.3109/15513811003777276
    [52] Bhat YR, Vinayaka G, Vani R, et al. Antenatal Bartter syndrome: a rare cause of unexplained severe polyhydra-mnios[J]. Ann Trop Paediatr, 2013, 31: 153-157.
    [53] Mani S, Nair J, Handa D. Antenatal Bartter syndrome: a new compound heterozygous mutation in exon 2 of KCNJ1 gene[J]. BMJ Case Rep, 2021, 14: e244685. doi:  10.1136/bcr-2021-244685
    [54] Francini F, Gobbi L, Ravarotto V, et al. The dietary approach to the treatment of the rare genetic tubulopathies Gitelman's and Bartter's syndromes[J]. Nutrients, 2021, 13: 2960. doi:  10.3390/nu13092960
    [55] Han Y, Cheng H, Shao S, et al. Thirteen novel CLCNKB variants and genotype/phenotype association study in 42 Chinese patients with Bartter syndrome type 3[J]. Endocrine, 2020, 68: 192-202. doi:  10.1007/s12020-019-02156-9
    [56] Gasongo G, Greenbaum LA, Niel O, et al. Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome[J]. Pediatr Nephrol, 2019, 34: 679-684. doi:  10.1007/s00467-018-4135-8
    [57] Plumb LA, Van't Hoff W, Kleta R, et al. Renal apnoea: extreme disturbance of homoeostasis in a child with Bartter syndrome type Ⅳ[J]. Lancet, 2016, 388: 631-632. doi:  10.1016/S0140-6736(16)00087-8
    [58] Zaffanello M, Taranta A, Palma A, et al. Type Ⅳ Bartter syndrome: report of two new cases[J]. Pediatr Nephrol, 2006, 21: 766-770. doi:  10.1007/s00467-006-0090-x
    [59] 韩玥, 郎艳华, 林毅, 等. 中国4例4a型巴特综合征BSND基因变异和临床表型分析[J]. 中华肾脏病杂志, 2021, 37: 851-853. doi:  10.3760/cma.j.cn441217-20200915-00129
    [60] Adachi M, Asakura Y, Sato Y, et al. Novel SLC12A1 (NKCC2) mutations in two families with Bartter syndrome type 1[J]. Endocr J, 2007, 54: 1003-1007. doi:  10.1507/endocrj.K06-204
    [61] Nagao R, Suzuki S, Kawashima H, et al. Acute kidney injury in type 3 Bartter syndrome: angiotensin-converting enzyme inhibitors as a cause[J]. Pediatr Int, 2016, 58: 1373-1374. doi:  10.1111/ped.13100
    [62] Bell DS. Successful utilization of aliskiren, a direct renin inhibitor in Bartter syndrome[J]. South Med J, 2009, 102: 413-415. doi:  10.1097/SMJ.0b013e31819b8673
    [63] Seyberth HW, Schlingmann KP. Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects[J]. Pediatr Nephrol, 2011, 26: 1789-1802. doi:  10.1007/s00467-011-1871-4
    [64] Kontorinis G, Giesemann AM, Iliodromiti Z, et al. Treating hearing loss in patients with infantile Bartter syndrome[J]. Laryngoscope, 2012, 122: 2524-2528. doi:  10.1002/lary.23532
    [65] Schurman SJ, Perlman SA, Sutphen R, et al. Genotype/phenotype observations in African Americans with Bartter syndrome[J]. J Pediatr, 2001, 139: 105-110. doi:  10.1067/mpd.2001.115020
    [66] Wu X, Yang G, Chen S, et al. Bartter syndrome with long-term follow-up: a case report[J]. J Int Med Res, 2020, 48: 300060520947876.
    [67] Yang X, Zhang G, Wang M, et al. Bartter syndrome type 3: phenotype-genotype correlation and favorable response to ibuprofen[J]. Front Pediatr, 2018, 6: 153. doi:  10.3389/fped.2018.00153
    [68] Sardani Y, Qin K, Haas M, et al. Bartter syndrome complicated by immune complex nephropathy. Case report and literature review[J]. Pediatr Nephrol, 2003, 18: 913-918. doi:  10.1007/s00467-003-1194-1
    [69] Zhu B, Jiang H, Cao M, et al. A novel CLCNKB mutation in a Chinese girl with classic Bartter syndrome: a case report[J]. BMC Med Genet, 2019, 20: 137. doi:  10.1186/s12881-019-0869-9
    [70] Mrad FCC, Soares SBM, de Menezes Silva LAW, et al. Bartter's syndrome: clinical findings, genetic causes and therapeutic approach[J]. World J Pediatr, 2021, 17: 31-39. doi:  10.1007/s12519-020-00370-4
    [71] Landau D, Gurevich E, Sinai-Treiman L, et al. Accentua-ted hyperparathyroidism in type Ⅱ Bartter syndrome[J]. Pediatr Nephrol, 2016, 31: 1085-1090. doi:  10.1007/s00467-016-3337-1
    [72] Dickson FJ, Sayer JA. Nephrocalcinosis: a review of monogenic causes and insights they provide into this heterogeneous condition[J]. Int J Mol Sci, 2020, 21: 369. doi:  10.3390/ijms21010369
    [73] Devuyst O, Belge H, Konrad M, et al. Renal tubular disorders of electrolyte regulation in children[J]. Pediatr Nephrol, 2016, 38: 1246-1252.
    [74] Landau D, Shalev L, Schneider E, et al. Bartter syndrome types 2 and 4: complications in currently treated young adults[J]. Pediatr Nephrol, 2016: 1743-1744.
    [75] Saha A, Pande P, Vala K, et al. Clinical exome sequencing uncovers an unsuspected diagnosis of Bartter syndrome type 2 in a child with incidentally detected nephrocalcinosis[J]. CEN Case Rep, 2022, 11: 417-421. doi:  10.1007/s13730-022-00694-2
    [76] Tian M, Peng H, Bi X, et al. Late-onset Bartter syndrome type Ⅱ due to a novel compound heterozygous mutation in KCNJ1 gene: a case report and literature review[J]. Front Med, 2022, 9: 862514. doi:  10.3389/fmed.2022.862514
    [77] Sharma A, Linshaw MA. A novel compound heterozygous ROMK mutation presenting as late onset Bartter syndrome associated with nephrocalcinosis and elevated 1, 25(OH)(2) vitamin D levels[J]. Clin Exp Nephrol, 2011, 15: 572-576. doi:  10.1007/s10157-011-0431-3
    [78] Bettinelli A, Ciarmatori S, Cesareo L, et al. Phenotypic variability in Bartter syndrome type Ⅰ[J]. Pediatr Nephrol, 2000, 14: 940-945. doi:  10.1007/PL00013418
    [79] Hsu IR, Kamil ES, Lemley KV, et al. Syndrome of antenatal Bartter-like syndrome, hyperparathyroidism, hypercalcemia, bilateral nephrocalcinosis and nephrogenic DI in three patients treated with cinacalcet[J/OL ]. (2019-07-16)[2023-04-15]. https://doi.org/10.1093/edrv/35.supp.1.
    [80] Novo R, Cartigny M, Lefevre C, et al. Bartter syndrome with bone-destroying hyperparathyroidism: about two cases, genetically proved, with long-lasting follow-up[J]. Horm Res Paediatr, 2016, 86: 173.
    [81] Rodríguez-Soriano J, Vallo A, Aguirre M. Bone mineral density and bone turnover in patients with Bartter syndrome[J]. Pediatr Nephrol, 2005, 20: 1120-1125. doi:  10.1007/s00467-005-1901-1
    [82] Gross I, Siedner-Weintraub Y, Simckes A, et al. Antena-tal Bartter syndrome presenting as hyperparathyroidism with hypercalcemia and hypercalciuria: a case report and review[J]. J Pediatr Endocrinol Metab, 2015, 28: 943-946.
    [83] He Y, Zhou Y, Wu W, et al. Bartter syndrome with multiple renal and liver cysts: a case report[J]. Int Urol Nephrol, 2022, 55: 225-228. doi:  10.1007/s11255-022-03274-6
    [84] Lee SE, Han KH, Jung YH, et al. Renal transplantation in a patient with Bartter syndrome and glomerulosclerosis[J]. Korean J Pediatr, 2011, 54: 36. doi:  10.3345/kjp.2011.54.1.36
    [85] Cha EJ, Hwang WM, Yun SR, et al. An adult case of Bartter syndrome type Ⅲ presenting with proteinuria[J]. J Pathol Transl Med, 2016, 50: 160-164. doi:  10.4132/jptm.2015.08.31
    [86] Carmody JB, Charlton JR. Short-term gestation, long-term risk: prematurity and chronic kidney disease[J]. Pediatrics, 2013, 131: 1168-1179. doi:  10.1542/peds.2013-0009
    [87] Chong L, Baikunje S, Poller DN, et al. An unusual cause of acute renal failure with volume depletion due to renal losses[J]. Am J Kidney Dis, 2008, 52: 366-369. doi:  10.1053/j.ajkd.2008.04.025
    [88] Khosravi M, Walsh SB. The long-term complications of the inherited tubulopathies: an adult perspective[J]. Pediatr Nephrol, 2014, 30: 385-395.
    [89] Reinalter SC, Gröne HJ, Konrad M, et al. Evaluation of longterm treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies[J]. J Pediatr, 2001, 139: 398-406. doi:  10.1067/mpd.2001.117007
    [90] Altneida OD, Spinnato JA. Maternal Bartter's syndrome and pregnancy[J]. Am J Obstet Gynecol, 1989, 160: 1225-1226. doi:  10.1016/0002-9378(89)90198-1
    [91] Deruelle P, Dufour P, Magnenant E, et al. Maternal Bartter's syndrome in pregnancy treated by amiloride[J]. Eur J Obstet Gynecol Reprod Biol, 2004, 115: 106-107. doi:  10.1016/j.ejogrb.2004.01.030
    [92] O'Sullivan E, Monga M, Graves W. Bartter's syndrome in pregnancy: a case report and review[J]. Am J Perinatol, 1997, 14: 55-57. doi:  10.1055/s-2007-994097
    [93] Rigó J Jr, Gláz E, Papp Z. Low or high doses of spironolactone for treatment of maternal Bartter's syndrome[J]. Am J Obstet Gynecol, 1996, 174: 297.
    [94] Nohira TNT, Akutagawa O, Fujito A, et al. Pregnancy complicated with Bartter's syndrome: a case report[J]. J Obstet Gynaecol Res, 2001, 27: 267-274. doi:  10.1111/j.1447-0756.2001.tb01268.x
    [95] Luqman A, Kazmi A, Wall BM, et al. Bartter's syndrome in pregnancy: review of potassium homeostasis in gestation[J]. Am J Med Sci, 2009, 338: 500-504. doi:  10.1097/MAJ.0b013e31819f1ed8
    [96] Peregrin-Alvarez I, Rodriguez-Casares J, Lucena-Herrera C, et al. Bartter's syndrome and pregnancy[J]. Eur J Obstet Gynecol Reprod Biol, 2005, 121: 118-119. doi:  10.1016/j.ejogrb.2004.12.005
    [97] Zhang L, Peng X, Zhao B, et al. Clinical and laboratory features of female Gitelman syndrome and the pregnancy outcomes in a Chinese cohort[J]. Nephrology, 2020, 25: 749-757. doi:  10.1111/nep.13743
    [98] Kannan S, Delph Y, Moseley HS. Anaesthetic manage-ment of a child with Bartter's syndrome[J]. Can J Anaesth, 1995, 42: 808-812. doi:  10.1007/BF03011183
    [99] Raza D, Khan FA. Anaesthetic management for hiatal hernia repair in a child with Bartter's syndrome: A case report[J]. J Pak Med Assoc, 2020, 70: 737-739.
    [100] Roelofse JA, van der Westhuijzen AJ. Anesthetic management of a patient with Bartter's syndrome undergoing orthognathic surgery[J]. Anesth Prog, 1997, 44: 71-75.
    [101] Kim JY, Kim GA, Song JH, et al. A case of living-related kidney transplantation in Bartter's syndrome[J]. Yonsei Med J, 2000, 41: 662-665. doi:  10.3349/ymj.2000.41.5.662
    [102] Nooh N, Abdullah W, Sheta S. Anesthetic management of a patient with Bartter's syndrome undergoing bilateral sagittal split osteotomy[J]. Saudi J Anaesth, 2012, 6: 419-422. doi:  10.4103/1658-354X.105895
    [103] Fujino S, Miyoshi N, Ohue M, et al. Rectal cancer in a patient with Bartter syndrome: a case report[J]. Genes, 2017, 8: 139. doi:  10.3390/genes8050139
    [104] Gallagher H, Soar J, Tomson C. New guideline for perioperative management of people with inherited salt-wasting alkaloses[J]. Br J Anaesth, 2016, 116: 746-749. doi:  10.1093/bja/aew102
  • 加载中
图(2) / 表(6)
计量
  • 文章访问数:  825
  • HTML全文浏览量:  118
  • PDF下载量:  669
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-04-20
  • 录用日期:  2023-05-15
  • 网络出版日期:  2023-06-09
  • 刊出日期:  2023-07-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!